Therapeutic Drug Monitoring of Antidepressants
暂无分享,去创建一个
[1] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[2] S. Preskorn,et al. Antidepressant Response and Plasma Concentrations of Fluoxetine , 1991 .
[3] S. Preskorn. Bupropion: What Mechanism of Action? , 2000 .
[4] A. T. Harvey,et al. Biochemical and clinical dose‐response curves with sertraline , 1996 .
[5] S. Preskorn. Antidepressant drug selection: criteria and options. , 1994, The Journal of clinical psychiatry.
[6] T. Cooper,et al. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. , 1984, Journal of pharmaceutical sciences.
[7] K. Brøsen,et al. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? , 2000, Therapeutic drug monitoring.
[8] S. Preskorn,et al. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. , 1994, The Journal of clinical psychiatry.
[9] J. Mendels,et al. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo , 1995, Biological Psychiatry.
[10] J. Amsterdam,et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. , 1997, The American journal of psychiatry.
[11] J. Cohn,et al. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. , 1985, The Journal of clinical psychiatry.
[12] K. Overø. Kinetics of citalopram in man; plasma levels in patients , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[13] E. A. Allen,et al. The pharmacokinetics of paroxetine in the elderly , 1989, Acta psychiatrica Scandinavica. Supplementum.
[14] S. Preskorn,et al. Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors , 1997, Clinical Pharmacokinetics.
[15] M. Dahl,et al. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. , 2000, Therapeutic drug monitoring.
[16] G. Tucker. Advances in understanding drug metabolism and its contribution to variability in patient response. , 2000, Therapeutic drug monitoring.
[17] W. Katon,et al. The Role of the Primary Care Physician in Patients' Adherence to Antidepressant Therapy , 1995, Medical care.
[18] P. Renshaw,et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. , 2000, The American journal of psychiatry.
[19] J. Wålinder,et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly , 1989, Acta psychiatrica Scandinavica. Supplementum.
[20] P Ley,et al. Satisfaction, compliance and communication. , 1982, The British journal of clinical psychology.
[21] P. Janicak. Principles and Practice of Psychopharmacotherapy , 1993 .
[22] C. Beasley,et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. , 1991, The Journal of clinical psychiatry.
[23] S. Preskorn. Should bupropion dosage be adjusted based upon therapeutic drug monitoring? , 1991, Psychopharmacology bulletin.
[24] R. Zerbe,et al. Fixed-dose fluoxetine therapy for depression. , 1987, Psychopharmacology bulletin.
[25] J. Wernicke,et al. Low-dose fluoxetine therapy for depression. , 1988, Psychopharmacology bulletin.
[26] P. Haffmans,et al. Venlafaxine serum levels and CYP2D6 genotype. , 2000, Therapeutic drug monitoring.
[27] A. Coppen,et al. Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. , 1983, British journal of clinical pharmacology.
[28] L Lemberger,et al. Fluoxetine: clinical pharmacology and physiologic disposition. , 1985, The Journal of clinical psychiatry.
[29] C. Bye,et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.
[30] T. Someya,et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. , 2000, Journal of clinical psychopharmacology.
[31] J. Davidson,et al. Seizures and bupropion: a review. , 1989, The Journal of clinical psychiatry.
[32] L. Tremaine,et al. Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female Volunteers , 1997, Clinical pharmacokinetics.
[33] P. Goodnick. Blood levels and acute response to bupropion. , 1992, The American journal of psychiatry.
[34] P. Goodnick. Pharmacokinetics of second generation antidepressants: fluoxetine. , 1991, Psychopharmacology bulletin.
[35] Altamura Ac,et al. The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression. , 1988 .
[36] S. Preskorn,et al. Therapeutic drug monitoring. Principles and practice. , 1993, The Psychiatric clinics of North America.
[37] J. Cummings,et al. The neuroanatomy of depression. , 1993, The Journal of clinical psychiatry.
[38] S. Preskorn. Selection of an antidepressant: mirtazapine. , 1997, The Journal of clinical psychiatry.
[39] S. Preskorn,et al. Tricyclic antidepressant-induced seizures and plasma drug concentration. , 1992, The Journal of clinical psychiatry.
[40] S. Preskorn,et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. , 1994, Journal of clinical psychopharmacology.
[41] M. Reis,et al. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. , 2000, Therapeutic drug monitoring.
[42] T. Cooper,et al. Human brain fluoxetine concentrations. , 1993, The Journal of neuropsychiatry and clinical neurosciences.
[43] J. Amsterdam,et al. What constitutes an adequate antidepressant trial for fluoxetine? , 1990, The Journal of clinical psychiatry.
[44] K. Brøsen,et al. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.
[45] D. Greenblatt,et al. Kinetic-dynamic modeling in clinical psychopharmacology. , 1993, Journal of clinical psychopharmacology.
[46] C. Reist,et al. Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[47] E. Richelson,et al. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. , 1993, Life sciences.
[48] D. Kupfer,et al. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. , 1990, The Journal of clinical psychiatry.
[49] Young Rc,et al. Desipramine: cardiovascular effects and plasma levels. , 1980 .
[50] P. Tyrer,et al. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor , 1987, Journal of psychopharmacology.
[51] S. Preskorn,et al. Somatic therapy for major depressive disorder: selection of an antidepressant. , 1992, The Journal of clinical psychiatry.
[52] Preskorn Sh. Introduction. Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. , 1993 .
[53] D. Klein,et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? , 1996, Archives of general psychiatry.
[54] M. Fava,et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. , 1992, The American journal of psychiatry.
[55] J. Cain. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? , 1992, The Journal of clinical psychiatry.
[56] G. Klerman,et al. Trends in the prescription of antidepressants by office-based psychiatrists. , 1993, The American journal of psychiatry.
[57] S. Preskorn,et al. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. , 1991, The Journal of clinical psychiatry.
[58] J. Fabricius,et al. Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man. , 2009, Acta pharmacologica et toxicologica.
[59] M. Garvey,et al. Serum Fluoxetine and Norfluoxetine Concentrations and Antidepressant Response , 1989, Therapeutic drug monitoring.
[60] J. Potvin,et al. Effect of dose escalation after low-dose fluoxetine therapy. , 1989, Psychopharmacology bulletin.
[61] Karen J. Klamerus,et al. Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite , 1992, Journal of clinical pharmacology.
[62] M. Kraml,et al. A High‐Performance Liquid Chromatographic Method for the Simultaneous Determination of Venlafaxine and O‐Desmethylvenlafaxine in Biological Fluids , 1994, Therapeutic drug monitoring.
[63] L. Balant,et al. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. , 1989, Therapeutic drug monitoring.
[64] B. Pfohl,et al. The Relationship Between Antidepressant Response and Tricyclic Antidepressant Plasma Concentrations , 1987, Clinical pharmacokinetics.
[65] W. Potter,et al. Bupropion in depression. II. The role of metabolites in clinical outcome. , 1988, Archives of general psychiatry.
[66] B. Pollock,et al. Bupropion plasma levels and CYP2D6 phenotype. , 1996, Therapeutic drug monitoring.
[67] S. Preskorn,et al. Bupropion Plasma Levels Intraindividual and Interindividual Variability , 1989 .
[68] R. Barbhaiya,et al. Clinical Pharmacokinetics of Nefazodone , 1997, Clinical pharmacokinetics.
[69] Osama Mawlawi,et al. Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans , 2001, Neuropsychopharmacology.
[70] E. Richelson. Pharmacology of antidepressants--characteristics of the ideal drug. , 1994, Mayo Clinic proceedings.
[71] S. Preskorn,et al. Plasma levels of imipramine and adverse effects in children. , 1983, The American journal of psychiatry.
[72] R. Gerner,et al. The dexamethasone suppression test and response to somatic treatment: a review. , 1986, The Journal of clinical psychiatry.
[73] T. Cooper,et al. Effect of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine , 1986, Neuropharmacology.
[74] C. Eap,et al. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. , 2000, Pharmacopsychiatry.
[75] K. Brøsen. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. , 1996, Therapeutic drug monitoring.
[76] S. Preskorn,et al. Central Nervous System Toxicity of Tricyclic Antidepressants: Phenomenology, Course, Risk Factors, and Role of Therapeutic Drug Monitoring , 1990, Journal of clinical psychopharmacology.
[77] P. Goodnick. Pharmacokinetics of second generation antidepressants: bupropion. , 1991, Psychopharmacology bulletin.
[78] D. H. Schroeder,et al. Therapeutic drug monitoring of bupropion. , 1990, The American journal of psychiatry.
[79] J. Haskins,et al. DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. , 1985, European journal of pharmacology.
[80] R. Veith,et al. Electrocardiogram changes and plasma desipramine levels during treatment of depression , 1980, Clinical pharmacology and therapeutics.
[81] S. Preskorn. Antidepressants: Neurochemical, Behavioral, and Clinical Perspectives , 1983 .
[82] G. Dunbar,et al. Optimal dose regimen for paroxetine. , 1992, The Journal of clinical psychiatry.
[83] M. Jerling. Dosing of antidepressants--the unknown art. , 1995, Journal of clinical psychopharmacology.
[84] G. Dunbar,et al. A pharmacokinetic dose titration study in adult and elderly depressed patients , 1989, Acta psychiatrica Scandinavica. Supplementum.
[85] M. Reis,et al. Serum Concentrations of Fluoxetine in the Clinical Treatment Setting , 2001, Therapeutic drug monitoring.
[86] P. Goodnick. Pharmacokinetic Optimisation of Therapy with Newer Antidepressants , 1994, Clinical pharmacokinetics.
[87] Recent developments in the pharmacotherapy of mood disorders. , 1996 .
[88] A. Rush,et al. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? , 1996, The American journal of psychiatry.
[89] S. Preskorn,et al. Evidence of the dual mechanisms of action of venlafaxine. , 2000, Archives of general psychiatry.
[90] J. Azuma,et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population , 2000, European Journal of Clinical Pharmacology.
[91] B. Rochat,et al. Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse‐Phase Liquid Chromatography , 1995, Therapeutic drug monitoring.
[92] P. Kragh‐Sørensen,et al. The kinetics of citalopram: single and multiple dose studies in man. , 2009, Acta pharmacologica et toxicologica.